Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
The peripheral blood CD4+/CD8+ T cell ratio is a potential predictive biomarker for the response to STRIDE therapy in HCC patients.
Authors
- Takuyo Kozuka (ORCID: https://orcid.org/0000-0002-4527-2638)
- Masaru Matsumura (ORCID: https://orcid.org/0000-0001-7898-7595)
- Yasuka Eriksson
- Yusuke Kawamura (ORCID: https://orcid.org/0000-0001-6148-0042)
- S. Okubo (ORCID: https://orcid.org/0000-0001-8235-5603)
- Kenji Ikeda (ORCID: https://orcid.org/0000-0001-8299-4464)
- Masaji Hashimoto (ORCID: https://orcid.org/0000-0003-0616-3348)
- Tetsuya Hosaka (ORCID: https://orcid.org/0000-0003-0302-2275)
- Hitomi Sezaki
- Licht Tominaga
- Norio Akuta (ORCID: https://orcid.org/0000-0001-5386-9672)
- Shigeki Yamamoto (ORCID: https://orcid.org/0000-0002-4937-4973)
- Yoshiyuki Suzuki
- Yasuji Arase
- Fumitaka Suzuki
- Hiromitsu Kumada
- Satoshi Saitoh
Institutions
- Toranomon Hospital (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1111/hepr.14188
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Ministry of Health, Labour and Welfare